TMCnet - World's Largest Communications and Technology Community



RBCC Moves to the Front Lines of the 3D Bioprinting Revolution
[January 20, 2014]

RBCC Moves to the Front Lines of the 3D Bioprinting Revolution

MIRAMAR BEACH, Fla. --(Business Wire)--

Rainbow Coral Corp. (OTCBB: RBCC) is well-positioned to capitalize on the revolution in medicine being spurred on by 3D printing technology thanks to the innovative BiO Assay, a new 3D bioprinting system developed by RBCC's joint venture partner, Nano3D Biosciences (n3D).

Many experts believe that 3D bioprinting equipment like the BiO Assay is poised to solve the complex problems faced by biotech firms by giving them the opportunity to test drugs on functional human tissues in order to better understand and predict a drug's effect on the body. The BiO Assay uses magnetism to assemble cells in 3D and into conditions that closely mimic those found in vivo, giving drug makers functional preclinical human tissues far more useful than any animal or test tube models.

And with better testing results will come bigger profits for drug companies, says RBCC CEO Kimberly Palmer.

"Research has been hampered for too long by traditional cell culture models that have proven to be poor predictors of drug efficacy and toxicity in humans," Palmer said. "The BiO Assay has been engineered to reduce costs and improve results across a broad spectrum of tests and assays. It provides a renewable and easy-to-use source of lifelike cell cultures that will change the way research is conducted across the globe."

The BiO Assay represents a revolution in pharmaceutical research, offering better and faster results than have previously been possible.

RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow Biosciences acquired an equity interest in n3D.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit For investment information and performance data on the Company, please visit

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy